Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.64 |
| ▸ | CDK1 | P06493 | 14/20 | 0.64 |
| ▸ | CCND1 | P24385 | 12/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.64 |
| ▸ | CDK2 | P24941 | 10/20 | 0.64 |
| ▸ | CDK9 | P50750 | 8/20 | 0.64 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.64 |
| ▸ | GSK3A | P49840 | 4/20 | 0.64 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.64 |
| ▸ | CDK7 | P50613 | 3/20 | 0.64 |
| ▸ | CCND3 | P30281 | 3/20 | 0.64 |
| ▸ | CCNH | P51946 | 2/20 | 0.64 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.64 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 0.64 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585801 | 1.00 | CDK4 (0.64) | CDK4CDK1CCND1CCNB1CDK2 | |
| Hydrochloric Acid SCHEMBL15636652 | 0.99 | CDK4 (0.65) | CDK4CDK1CCND1CCNB1CDK2 | |
| Hydrochloric Acid SCHEMBL4447778 | 0.99 | CDK4 (0.65) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL5735816 | 0.89 | CDK4 (0.53) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL23683032 | 0.88 | CDK4 (0.75) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL20181812 | 0.88 | CDK4 (0.75) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL24669074 | 0.87 | CDK4 (0.74) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL22580714 | 0.85 | CDK4 (0.67) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL8821026 | 0.83 | CDK4 (0.60) | CDK4CDK1CCND1CCNB1CDK2 | |
| SCHEMBL16722415 | 0.82 | CDK4 (0.64) | CDK4CDK1CCND1CCNB1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503923-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Eisai R&D Management Co., Ltd. (JP) | 2019-07-03 | — | — | EP | claimed |
| WO-2018039324-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | WO | claimed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| EP-3503923-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Eisai R&D Management Co., Ltd. (JP) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039324-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | WO | disclosed |
| EP-2747755-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| US-20010011076-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2001-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011076-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | PRKCI, PRKCA, PRKCH | CDK4 310/4885CDK1 314/4885CCND1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.